This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kohl, N E Articles by Dixon, R A Search for Related Content PubMed PubMed Citation Articles by Kohl, N E Articles by Dixon, R A

 Previous Article  |  Next Article 

J Virol. 1991 June; 65(6): 3007-3014

Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.

Department of Molecular Biology, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.

ABSTRACT

To generate nonpathogenic viral particles which express active human immunodeficiency virus type 1 (HIV-1) protease (PR), plasmids containing sequences from the genomes of HIV-1 and Moloney murine leukemia virus (M-MuLV) were constructed. Either the PR coding region alone; the gag, PR, and reverse transcriptase protein-coding regions; or the complete gag and pol protein-coding regions from HIV-1 were substituted for the corresponding regions of a full-length M-MuLV clone to yield the chimeric plasmids pMoHIV-I, pMoHIV-III, and pMoHIV-IV, respectively. Cell lines which express the viral gag polyprotein were isolated for hybrids pMoHIV-I and pMoHIV-III. These cells produced viral particles which contained processed core proteins. Cleavage of the gag polyprotein in the viral particles was inhibited by the HIV-1 PR inhibitor L-687908, indicating that the viral PR is responsible for the observed processing. The hybrid virions were not infectious; analyses indicated that the viral particles contained little or no reverse transcriptase activity. In addition, particles produced by pMoHIV-III transfectants failed to package the viral genomic RNA. The cell line which expresses and processes the HIV-1 gag polyprotein is a safe and effective reagent for the in vivo evaluation of potential inhibitors of the HIV-1 PR.

This article has been cited by other articles:

• Feher, A., Boross, P., Sperka, T., Miklossy, G., Kadas, J., Bagossi, P., Oroszlan, S., Weber, I. T., Tozser, J. (2006). Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.. J. Gen. Virol. 87: 1321-1330 [Abstract] [Full Text]  
• Woerle, H. J., Mariuz, P. R., Meyer, C., Reichman, R. C., Popa, E. M., Dostou, J. M., Welle, S. L., Gerich, J. E. (2003). Mechanisms for the Deterioration in Glucose Tolerance Associated With HIV Protease Inhibitor Regimens. Diabetes 52: 918-925 [Abstract] [Full Text]  
• Reed, M., Mariani, R., Sheppard, L., Pekrun, K., Landau, N. R., Soong, N.-W. (2002). Chimeric Human Immunodeficiency Virus Type 1 Containing Murine Leukemia Virus Matrix Assembles in Murine Cells. J. Virol. 76: 436-443 [Abstract] [Full Text]  
• Robinson, B. S., Riccardi, K. A., Gong, Y.-f., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., Lin, P.-f. (2000). BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrob. Agents Chemother. 44: 2093-2099 [Abstract] [Full Text]  
• Boden, D., Markowitz, M. (1998). Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 42: 2775-2783 [Full Text]